A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Participants With Locally Recurrent or Metastatic Breast Cancer
NCT01740336
Completed
This multicenter, randomized, single-blind, placebo-controlled, two arm study will evaluate the efficacy and safety of paclitaxel with GDC-0941 versus paclitaxel with placebo in participants with locally recurrent or metastatic breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/21/2017
Locations: Arizona Oncology Associates, PC - NAHOA, Sedona, Arizona +96 locations
Conditions: Breast Cancer
Register for Updates
Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without Pictilisib in Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer
NCT01493843
Completed
This multicenter, randomized, double-blind, placebo-controlled trial will evaluate the efficacy and safety of carboplatin/paclitaxel and carboplatin/paclitaxel/bevacizumab with and without pictilisib in particpants with previously untreated advanced or recurrent non-small cell lung cancer (NSCLC). Particpants will be randomized to receive 4 cycles of carboplatin (C)/paclitaxel (P) and either pictilisib or placebo, with (participants with non-squamous NSCLC) or without (participants with squamous... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/21/2017
Locations: Alabama Oncology, Birmingham, Alabama +119 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates
N-acetylcysteine Given IV With Cisplatin and Paclitaxel in Patients With Ovarian Cancer
NCT01138137
Withdrawn
RATIONAL FOR STUDYING IV NAC AS POTENTIAL CHEMOPROTECTANT: Cisplatin has shown efficacy in the treatment of subjects with epithelial ovarian cancer. Systemic toxicities associated with cisplatin include nephro, oto, and nerve toxicities. It may be possible to reduce the toxicities of cisplatin by administering it in conjunction with IV NAC. NAC may reduce cisplatin related nephro, oto, and nerve toxicities without compromising the effectiveness of the chemotherapy against the ovarian cancer cel... Read More
Gender:
FEMALE
Ages:
Between 18 years and 75 years
Trial Updated:
04/19/2017
Locations: Oregon Health & Science University, Portland, Oregon
Conditions: Ovarian Carcinoma, Stage 3 or 4, Epithelial Ovarian Carcinoma, Primary Peritoneal Carcinoma
Register for Updates
Study of Paclitaxel/Carboplatin With or Without Bavituximab in Previously Untreated Non Small-Cell Lung Cancer
NCT01160601
Completed
This is a randomized, open-label, multicenter, phase 2 study comparing Paclitaxel/Carboplatin with or without bavituximab in patients that have previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/18/2017
Locations: Ironwood Cancer and Research Center, Chandler, Arizona +39 locations
Conditions: Non-Squamous Non-Small Cell Lung Cancer
Register for Updates
Hydroxychloroquine, Carboplatin, Paclitaxel, and Bevacizumab in Recurrent Advanced Non-Small Cell Lung Cancer
NCT00728845
Terminated
RATIONALE: Drugs used in chemotherapy, such as hydroxychloroquine, carboplatin, and paclitaxel and work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cell... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
04/17/2017
Locations: Cancer Institute of New Jersey at Hamilton, Hamilton, New Jersey +1 locations
Conditions: Lung Cancer
Register for Updates
Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer
NCT00041119
Completed
This randomized phase III trial studies cyclophosphamide and doxorubicin hydrochloride compared with paclitaxel as adjuvant therapy in treating breast cancer in women with 0-3 positive axillary lymph nodes. Giving additional cancer treatment after surgery may help to lower the risk that the cancer will come back (adjuvant therapy). Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by k... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/12/2017
Locations: Regional Medical Center, Anniston, Alabama +526 locations
Conditions: Breast Cancer
Register for Updates
Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer
NCT02243007
Terminated
This research study is a Phase II clinical trial, which evaluates a combination of drugs, FOLFIRINOX and Gemcitabine/Nab-Paclitaxel, in the management of participants with resectable pancreatic cancer prior to surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2017
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Resectable Pancreatic Cancer, Pancreatic Ductal Carcinoma
Register for Updates
Neoadjuvant Chemotherapy Using Doxorubicin and Paclitaxel in Treating Women With Large Breast Cancer
NCT00096291
Completed
RATIONALE: Drugs used in chemotherapy, such as doxorubicin and paclitaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy before and after surgery may shrink the tumor so it can be removed and may kill any tumor cells remaining after surgery. PURPOSE: This randomized phase II trial is comparing two different regimens of doxorubicin and paclitaxel to see how well they work in treating women who are undergoing surgery for breast cancer.
Gender:
FEMALE
Ages:
Between 18 years and 120 years
Trial Updated:
04/07/2017
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts +1 locations
Conditions: Breast Cancer
Register for Updates
Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer
NCT00482391
Completed
The purpose of this study is to study a new treatment for HER-2/neu (+) breast cancer.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
04/06/2017
Locations: Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts +1 locations
Conditions: Breast Cancer
Register for Updates
Abraxane Therapy in Patients With Pancreatic Cancer Who Failed First-Line Gemcitabine Therapy
NCT00691054
Completed
RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well paclitaxel albumin-stabilized nanoparticle formulation works in treating patients with locally advanced or metastatic pancreatic cancer that did not respond to first-line therapy with gemcitabine.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
04/04/2017
Locations: University of Miami Sylvester Comprehensive Cancer Center - Miami, Miami, Florida +1 locations
Conditions: Pancreatic Cancer
Register for Updates
BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors
NCT01297452
Completed
The purpose of this study is to find out the good and bad effects that occur when BKM120 is added to standard chemotherapy with carboplatin and paclitaxel.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/30/2017
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Solid Tumors
Register for Updates
Cisplatin and Nab-paclitaxel for (N2) Defined NSCLC
NCT02276560
Terminated
The purpose of this research study is to determine whether giving cisplatin and nab-paclitaxel before surgery will reduce the presence of disease in certain areas of the lung at the time of surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/29/2017
Locations: Moffitt Cancer Center, Tampa, Florida +8 locations
Conditions: Stage IIIA Non-Small Cell Lung Cancer
Register for Updates